Back

The cost-effectiveness of PCSK9 inihibitors in Australia

27 August 2017 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster session 2 - Lipids Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Ella Zomer

Monash University, Victoria (Australia)

14 More presentations in this session

Presentation thumbnail
Professor B. Cariou (Nantes, FR)
Abstract
Presentation thumbnail
Doctor L. Pedersen (Copenhagen, DK)
Abstract
Presentation thumbnail
Doctor J. Meeusen (Rochester, US)
Abstract
Presentation thumbnail
Associate Professor R. Santos (Sao Paulo, BR)
Abstract
Presentation thumbnail
Doctor R. Nishikawa (Osaka, JP)
Abstract

Access the full session

Session thumbnail
Poster session 2 - Lipids

The Event

Event poster

ESC Congress 2017

27 August 2017 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Cost impact of the ESC/EAS 2019 dyslipidemia guidelines recommended use of PSCK9i in very-high-risk patients with an LDL <1.8mmol/L for secondary prevention
26 August 2023
thumbnail
Congress Presentation
Review on clinical strategies for managing patients with elevated Lp(a): Cost-effectiveness of Lp(a) testing and awareness of lifestyle changes via Public Health Policy in absence of targeted therapy
24 June 2023
thumbnail
Congress Presentation
Effectiveness of PCSK9 inhibitors in homozygous familial hypercholesterolemia: insights from a Saudi Arabia genetic population
3 April 2025
thumbnail
Congress Presentation
Cost-effectiveness of Sacubitril/Valsartan in acute and chronic heart failure with reduced ejection fraction: from randomized controlled trials to real-world evidence
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources